Treatment of malignant brain tumours by complementation
Glioblastoma is the most common primary brain tumour in humans. It is a diagnosis with a very bleak outcome. The goal is to analyse whether glioblastoma expresses C1-IA and CRP (proteins) that inhibit immune response by inactivating the complement system, and to test treatment in various animal models for glioblastoma.